This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1978;43(3-4):279-86.

doi: 10.1007/BF01246965.

Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor

J Mendlewicz, M B Youdim

PMID: 745020
DOI: 10.1007/BF01246965

Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor

J Mendlewicz et al. J Neural Transm. 1978.

. 1978;43(3-4):279-86.

doi: 10.1007/BF01246965.

Authors

J Mendlewicz, M B Youdim

PMID: 745020
DOI: 10.1007/BF01246965

No abstract available

PubMed Disclaimer

Similar articles

(-)Deprenyl in the treatment of Parkinson's disease.
Birkmayer W, Riederer P, Youdim MB. Birkmayer W, et al. Clin Neuropharmacol. 1982;5(2):195-230. doi: 10.1097/00002826-198205020-00004. Clin Neuropharmacol. 1982. PMID: 6814755 No abstract available.
L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.
Mann J, Gershon S. Mann J, et al. Life Sci. 1980 Mar 17;26(11):877-82. doi: 10.1016/0024-3205(80)90350-1. Life Sci. 1980. PMID: 6768943 No abstract available.
Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness.
Mendlewicz J, Youdim MB. Mendlewicz J, et al. J Affect Disord. 1980 Jun;2(2):137-46. doi: 10.1016/0165-0327(80)90013-0. J Affect Disord. 1980. PMID: 6448885 Clinical Trial.
R-(-)-deprenyl and parkinsonism.
Yahr MD. Yahr MD. J Neural Transm Suppl. 1987;25:5-12. J Neural Transm Suppl. 1987. PMID: 3123605 Review.
Selegiline in the treatment of Parkinson's disease.
Heinonen EH, Rinne UK. Heinonen EH, et al. Acta Neurol Scand Suppl. 1989;126:103-11. doi: 10.1111/j.1600-0404.1989.tb01789.x. Acta Neurol Scand Suppl. 1989. PMID: 2515715 Review.

See all similar articles

Cited by

Effects of L-deprenyl on human growth hormone secretion.
Koulu M, Lammintausta R. Koulu M, et al. J Neural Transm. 1981;51(3-4):223-31. doi: 10.1007/BF01248954. J Neural Transm. 1981. PMID: 6793694
Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B.
Kalir A, Sabbagh A, Youdim MB. Kalir A, et al. Br J Pharmacol. 1981 May;73(1):55-64. doi: 10.1111/j.1476-5381.1981.tb16771.x. Br J Pharmacol. 1981. PMID: 7284698 Free PMC article.
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
Youdim MBH. Youdim MBH. J Neural Transm (Vienna). 2018 Nov;125(11):1719-1733. doi: 10.1007/s00702-018-1942-9. Epub 2018 Oct 19. J Neural Transm (Vienna). 2018. PMID: 30341696 Review.
Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated?
Askenasy JJ, Yahr MD. Askenasy JJ, et al. J Neural Transm. 1988;72(1):67-76. doi: 10.1007/BF01244633. J Neural Transm. 1988. PMID: 3379388
MAO-inhibitors in Parkinson's Disease.
Riederer P, Laux G. Riederer P, et al. Exp Neurobiol. 2011 Mar;20(1):1-17. doi: 10.5607/en.2011.20.1.1. Epub 2011 Mar 31. Exp Neurobiol. 2011. PMID: 22110357 Free PMC article.

See all "Cited by" articles

References

1. Lancet. 1970 May 9;1(7654):967-9 - PubMed
1. Lancet. 1977 Oct 15;2(8042):791-5 - PubMed
1. Nature. 1977 Jan 6;265(5589):80-1 - PubMed
1. Arch Gen Psychiatry. 1972 Jan;26(1):57-63 - PubMed
1. Lancet. 1977 Feb 26;1(8009):439-43 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer